Strategy

Cosmo’s business goal is to become a fully-integrated specialty pharmaceutical company, recognized for its excellence in treating selected gastro-intestinal (GI) diseases. Cosmo is pursuing this goal by following key elements of the business strategy:

• Long-term value creation by developing and marketing its own range of proprietary drug formulations.
• Cosmo intends to fund all clinical trials on its own and to bring products on the market. The company intends to control and engage the entire value chain from preclinical development to commercialization.
• Leveraging the benefits of the MMX® platform in order to create new pharmaceutical products. In a first step Cosmo will focus on Inflammatory Bowel Diseases (IBD), then the company will leverage the MMX® technology also for medical treatment of other conditions of the colon. Thus, the company plans to be able to offer the full range of drugs for the treatment of various states and forms of Inflammatory Bowel Disease, as shown on the image below.
  
• Developing a specific marketing and sales strategy for the United States and sales partnerships in the other countries for the proprietary drugs.
• Leveraging the manufacturing business in order to enhance growth. The Group intends to further grow its drug manufacturing business by offering high quality manufacturing services and in particular by its ability to manufacture tablets for the US market for third parties.